A Pilot study to evaluate paclitaxel (Taxol™) as primary medical treatment for patients with inoperable stage III and IV breast carcinoma
| Autor: | C.N. Rees, R.C. Coombes, J. English, C. Lowdell, D. Sinnett |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Paclitaxel Nausea medicine.medical_treatment Breast Neoplasms Pilot Projects Context (language use) chemistry.chemical_compound Internal medicine Carcinoma medicine Humans Neoplasm Staging Chemotherapy business.industry Middle Aged medicine.disease Antineoplastic Agents Phytogenic Combined Modality Therapy Discontinuation Surgery Radiation therapy Treatment Outcome chemistry Female medicine.symptom business Breast carcinoma |
| Zdroj: | European Journal of Cancer. 32:2354-2356 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/s0959-8049(96)00348-6 |
| Popis: | The activity of paclitaxel has been extensively investigated in previously treated patients with metastatic breast carcinoma. We evaluated the activity of paclitaxel as primary medical therapy in patients with stage III and IV breast carcinoma. 6 female patients were recruited with no previous history of surgery, radiotherapy or chemotherapy. Paclitaxel was administered as a 3-h infusion at a dose of 225 mg/m 2 repeated every 3 weeks weekly to a maximum of 10 cycles. 2 patients achieved a complete response, one of whom had a normal trucut biopsy of the affected breast 6 months after discontinuation of chemotherapy and radiotherapy and a normal mammogram at 17 months. 3 patients achieved a partial response and one stabilised. The patients received between four and ten cycles of chemotherapy. Paclitaxel at this dose was associated with toxicity including alopecia, stomatitis, nausea and diarrhoea. Moderately severe neutropenia occurred in 4 patients, 2 requiring antibiotics but was of short duration and did not necessitate a dose reduction for subsequent courses. Paclitaxel has shown activity as primary medical therapy in patients with inoperable breast carcinoma at presentation at this dosage and schedule. One patient achieved a complete response and avoided surgery altogether and all 6 patients had their primary tumour downgraded. It may be indicated as a single agent in this context or in combination with other drugs with proven activity in breast carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect